Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis
NCT ID: NCT00645073
Last Updated: 2008-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
271 participants
INTERVENTIONAL
2003-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
cefdinir (Omnicef)
Two 300 mg cefdinir capsules on Study Days 1-10.
B
levofloxacin
Two 250 mg levofloxacin capsules on Study Days 1-10
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cefdinir (Omnicef)
Two 300 mg cefdinir capsules on Study Days 1-10.
levofloxacin
Two 250 mg levofloxacin capsules on Study Days 1-10
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A condition of general good health, based upon the results of a medical history, physical examination, and laboratory profile.
* Subject must have a diagnosis of acute bacterial sinusitis. The diagnosis must be based on the following:
* a sinus radiograph or CT scan performed within 48 hours pre-treatment
* with evidence of maxillary opacification or air/fluid levels
* Purulent discharge from the nose
* At least one of the following clinical signs and symptoms of acute bacterial sinusitis
* Lasting for more than 7 days prior to and no longer than 21 days before Evaluation 1: facial pain over the sinus or facial pressure over the sinus or facial tightness over the sinus or facial swelling or toothache.
* Subject must be a suitable candidate for oral antimicrobial therapy and is able to swallow capsules intact.
Exclusion Criteria
* Significant anatomical abnormalities of the sinuses
* Any other infection or condition which necessitates use of a concomitant systemic antimicrobial.
* History of any hypersensitivity or allergic reactions to penicillins, cephalosporins (including cefdinir), or quinolones (including levofloxacin).
* Subject who has taken: a systemic antibiotic within 14 days before study drug administration; a long acting injectable antibiotic (e.g., penicillin G benzathine) within 30 days before study drug administration.
* Known significant renal or hepatic impairment.
* Evidence of uncontrolled clinically significant cardiovascular, pulmonary, metabolic, gastrointestinal, neurological or endocrine disease, malignancy, or other abnormality (other than the disease being studied).
* Investigator considers the subject unsuitable for cefdinir or levofloxacin therapy, for any reason.
* Previous enrollment in this study.
* Any underlying condition or disease state that would interfere with the completion of the study procedures and evaluations or absorption of study drug.
* Subject who is currently receiving or who is likely to require any of the following medications during the period between Evaluation 1 (initial presentation to office/clinic) and Evaluation 3 (or within 48 hours after the last dose of study drug): Concomitant theophylline or any theophylline analog, unless plasma levels of these drugs can be adequately monitored during the study; Warfarin and probenecid.
* Immunocompromised subjects.
* Subject who requires parenteral antibiotic therapy for this infection or who has any other infection or condition, that necessitates use of a concomitant systemic antibiotic.
* Subjects receiving antacids containing magnesium, or aluminum, as well as sucralfate, metal cations such as iron, and multivitamin preparations with zinc within 2 hours before or after dosing with study drug.
* Subjects with a known or suspected central nervous system disorder that may predispose the subject to seizures or lower the seizure threshold.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Abbott
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Birmingham, Alabama, United States
Columbiana, Alabama, United States
Eclectic, Alabama, United States
Tuscaloosa, Alabama, United States
Mesa, Arizona, United States
Fresno, California, United States
Fresno, California, United States
Murray, Kentucky, United States
Portage, Michigan, United States
Eugene, Oregon, United States
Lake Oswego, Oregon, United States
Orangeburg, South Carolina, United States
Kingsport, Tennessee, United States
Milan, Tennessee, United States
Corsicana, Texas, United States
San Antonio, Texas, United States
Salt Lake City, Utah, United States
Salt Lake City, Utah, United States
West Jordan, Utah, United States
West Jordan, Utah, United States
Winchester, Virginia, United States
Spokane, Washington, United States
Gorzów Wielkopolski, , Poland
Krakow, , Poland
Krakow, , Poland
Lodz, , Poland
Lodz, , Poland
Przybysławice, , Poland
Skierniewice, , Poland
Szczecin, , Poland
Szczecin, , Poland
Szczecin, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M03-628
Identifier Type: -
Identifier Source: org_study_id